TORONTO, ON / ACCESSWIRE / January 7, 2025 / ProteinQure, a leader in computational peptide design, is proud to announce the ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

CBX-12 is under clinical development by Cybrexa and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

TORONTO, ON / ACCESSWIRE / January 7, 2025 / ProteinQure, a leader in computational peptide design, is proud to announce the addition of two distinguished leaders to its team. Dr. Dave Garman has been ...

peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki ...

R&D Daily丨DaShi Pharmaceutical's first IND application for a new antibody drug targeting NGF was accepted ChK1 inhibitor!

providing unrivalled access to 30+ speakers discussing innovation and development in bispecific-drug conjugates, antibody-oligonucleotide conjugates, peptide-drug conjugates plus many other novel ...

Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...

INR:2922. crypto casino without kyc East Sunshine Pharmaceutical to win 1.5 billion antithrombotic drug Precision-guided myeloma drug! Melflufen, the fi ...

Drug discovery and novel disease treatments ... which the team termed Exosome Binding Peptide (EBP). The team found that “addition of EBP to an unrelated protein directed secretion on ...

INR:9130. delhi satta 2020 chart “First-in-class” peptide-drug conjugate receives accelerated approval from FDA eLife: Asthma may increase the risk of ...